GD2 and GD3 synthase: novel drug targets for cancer therapy

Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against...

Descripción completa

Detalles Bibliográficos
Autores principales: Sphyris, Nathalie, Sarkar, Tapasree Roy, Battula, Venkata L, Andreeff, Michael, Mani, Sendurai A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905286/
https://www.ncbi.nlm.nih.gov/pubmed/27308452
http://dx.doi.org/10.4161/23723556.2014.975068
_version_ 1782437240311382016
author Sphyris, Nathalie
Sarkar, Tapasree Roy
Battula, Venkata L
Andreeff, Michael
Mani, Sendurai A
author_facet Sphyris, Nathalie
Sarkar, Tapasree Roy
Battula, Venkata L
Andreeff, Michael
Mani, Sendurai A
author_sort Sphyris, Nathalie
collection PubMed
description Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.
format Online
Article
Text
id pubmed-4905286
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052862016-06-15 GD2 and GD3 synthase: novel drug targets for cancer therapy Sphyris, Nathalie Sarkar, Tapasree Roy Battula, Venkata L Andreeff, Michael Mani, Sendurai A Mol Cell Oncol Author's Views Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers. Taylor & Francis 2015-03-09 /pmc/articles/PMC4905286/ /pubmed/27308452 http://dx.doi.org/10.4161/23723556.2014.975068 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's Views
Sphyris, Nathalie
Sarkar, Tapasree Roy
Battula, Venkata L
Andreeff, Michael
Mani, Sendurai A
GD2 and GD3 synthase: novel drug targets for cancer therapy
title GD2 and GD3 synthase: novel drug targets for cancer therapy
title_full GD2 and GD3 synthase: novel drug targets for cancer therapy
title_fullStr GD2 and GD3 synthase: novel drug targets for cancer therapy
title_full_unstemmed GD2 and GD3 synthase: novel drug targets for cancer therapy
title_short GD2 and GD3 synthase: novel drug targets for cancer therapy
title_sort gd2 and gd3 synthase: novel drug targets for cancer therapy
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905286/
https://www.ncbi.nlm.nih.gov/pubmed/27308452
http://dx.doi.org/10.4161/23723556.2014.975068
work_keys_str_mv AT sphyrisnathalie gd2andgd3synthasenoveldrugtargetsforcancertherapy
AT sarkartapasreeroy gd2andgd3synthasenoveldrugtargetsforcancertherapy
AT battulavenkatal gd2andgd3synthasenoveldrugtargetsforcancertherapy
AT andreeffmichael gd2andgd3synthasenoveldrugtargetsforcancertherapy
AT manisenduraia gd2andgd3synthasenoveldrugtargetsforcancertherapy

Ejemplares similares